ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Clinical Practice Session

Renal Toxicities of Newer Cancer Therapies: A Clinicopathological Approach

October 23, 2020 | 10:00 AM - 12:00 PM

Location: On-Demand

Session Description

The field of onconephrology is rapidly expanding. With this comes increasing incidence of renal toxicity due to anticancer medications. This session describes recent advances in this rapidly changing field, including learning risk factors, clinical presentation, and management of AKI that occurs after immunotherapy and other oncologic therapies.

Learning Objective(s)

  • Identify risk factors, characteristics, and challenges in the diagnosis and management of AKI in onconephrology
  • Describe the features of immune checkpoint inhibitor-induced AKI
  • Discuss the risks and characteristics of chimeric antigen receptor T cell (CAR-T)-associated AKI
  • Examine the thrombotic microangiopathies in onconephrology

Learning Pathway(s)

  • Acute Kidney Injury
  • Pathology


  • Abhijat Kitchlu, MD, MS
  • Megan L. Troxell, MD, PhD


  • Risk Factors, Diagnosis, and Management of Immune Checkpoint Inhibitor-Associated AKI
    10:00 AM - 10:30 AM
    Meghan E. Sise, MD, MS 
  • Renal Lesions Associated with Immune Checkpoint Inhibitors: A Pathologic Analysis
    10:30 AM - 11:00 AM
    Leal C. Herlitz, MD 
  • AKI After Chimeric Antigen Receptor T Cell Chimeric Antigen Receptor T Cell (CAR-T) Therapies
    11:00 AM - 11:30 AM
    Jonathan Hogan, MD
  • Drug-Induced Thrombotic Microangiopathy
    11:30 AM - 12:00 PM
    Kammi J. Henriksen, MD